Almost all patients with advanced prostate cancer progress to castration resistant stage with limited treatment options. Oncolytic adenoviruses have been actively pursued as potential agents for cancer treatment. Virtually all clinical trials on oncolytic adenovirus are based on serotype 5.
Introduction
For the past 70 years, androgen deprivation achieved by chemical or surgical castration, has been the standard of care for men with prostate cancer. However, the response to treatment is not durable, and with time, the disease often progresses invariably into the fatal castration-resistant prostate cancer (CRPC) (1) (2) . Despite some promising preliminary results from new treatments designed to block androgen receptor activity (such as MDV3100 and abiraterone), it is still uncertain that androgen receptor reactivation is the only cause of castration resistance or that abrogation of androgen receptor signaling will result in cure (3) .
Virotherapy represents one of the most intensely studied gene therapy strategies for a variety of malignancies, including prostate cancer. It utilizes genetically engineered viruses for selective infection and killing of tumor cells while sparing normal cells. Several clinical trials using oncolytic adenoviruses have been carried out and promising results have been reported (4-7).
Human Adenovirus serotype 5 (Ad5) is the most extensively used platform for the development of oncolytic Ad. However, recently we and other groups found that binding of blood coagulation factors (particularly factor X) to Ad5 hexon mediates the hepatocytes uptake of Ad5, resulting in intolerable hepatotoxicity after intravenous injection (i.v.) for systemic treatment (8) (9) (10) (11) (12) . Moreover, when Ad5-based oncolytic vectors are intravenously injected for treatment of metastatic disease, much of its full potential has been limited by: 1) rapid removal of virions by the reticuloendothelial system, particularly liver Kupffer cells (KCs) as previously reported (13) (14) (15) ; 2) pre-existing neutralizing antibody against Ad5 in up to 90% of human subjects (12, (16) (17) .
The existence of > 50 human and > 100 nonhuman Ads with differences in tropism, safety, and seroprevalence suggests the possibility of increasing the portfolio of therapeutic adenoviruses by choosing those with most attractive features (12) (13) 18) . Ad6, although belongs to species C as Ad5, was reported to has 40% less of charge clusters in hypervariable regions (HVR) of hexon as compared to Ad5 (13) absorption by KCs, indicating that Ad6 might be one of the potential candidate adenoviruses (12) (13) 19 ).
To further detarget hepatocytes after systemic administration of Ad6, we hypothesized that silencing Ad6 E1A gene by a liver-specific microRNA would prevent the viral replication in hepatocytes, while not altering its antitumor effects. MicroRNAs are expressed in tissue-and differentiation state-specific patterns and are often differentially expressed or deleted in various cancers (20) (21) . Recent studies show that endogenous microRNAs could be exploited to control Ad5 replication. Incorporation of the tissue-specific microRNA target sequences into E1A expression cassette selectively suppressed the Ad5 replication in normal tissues and decreased the virus-related systemic toxicity, while maintained the comparable antitumor efficacy after i.v. injection (22) (23) (24) (25) .
MicroRNA miR122 is one of the candidates, which is abundantly expressed only in hepatocytes (26) (27) . Therefore we incorporated the complementary sequences for miR122 into the E1A expression cassette of Ad6 and generated a novel post-transcriptional liver-detargeted Ad6, designated Ad6miR. Our data show that Ad6miR further reduces the liver toxicity to normal level after systemic delivery; liver sinusoidal endothelial cells (LSECs), rather than generally recognized KCs, might serve as the major scavenger for the rapid clearance of Ad6 from blood circulation. Improved liver safety of Ad6miR allows increasing injection doses, which increases the anticancer activity against castration-resistant prostate cancer. 
Materials and methods

Adenoviruses and cells
Ad6 was obtained from American Type Culture Collection. Ad6 genomic DNA was extracted from infected A549 cells (28) ; the plasmid containing the Ad6 and Ad6miR genomic DNA were constructed as indicated in Fig. 1 . All viruses were generated by transfecting 293 cells and grown in A549 cells. Purified virus stocks were titred with OD260 using standard protocol (8) . dl309 was used as wide-type Ad5.
All cell lines were purchased from ATCC except where indicated. Human hepatocellular carcinoma cells HepG2 and Huh7, lung cancer A549, HEK293 and murine monocyte-macrophage cells RAW264.7 were cultured in DMEM with 10% FBS. The normal human lung fibroblasts (NHLF) and normal human hepatocytes (Nheps; Lonza, Switzerland) were cultured in the medium recommended by the manufacturer. Human prostate cancer cells PC3 and DU145 were maintained in RPMI 1640 medium plus 10% FBS. All cells lines were passaged within six months of receiving from the established cell bank and characterized with DNA profiling by the cell bank. The cells were tested to be Mycoplasma free by PCR methods before this study. All metastatic bone cancer samples were collected from patients with pathologically confirmed bone metastatic prostate cancer under the written informed consent and protocols approved by the Institutional Review Board. The primary cancer cells were isolated and maintained in DMEM plus Glutamax supplemented with 15% FBS.
Quantification of miR122 and E1A microRNA levels and viral genomic DNA cDNAs were synthesized using from 1.0 µg extracted total RNA according to standard protocol.
Endogenous miR122 expression was then determined with TaqMan microRNA assay kit (Applied Biosystems). E1A microRNA expression was determined as routine quantitative RT-PCR.
Amplification of mouse or human snRNA U6 served as an endogenous control to normalize the miRNA expression data. Viral genomic DNA was quantified by qPCR as previously reported (8) . Cells were infected with adenoviral vectors (100 vp/cell). Viral titers of 3 and 48 hr samples were determined as described earlier (8) . Viral burst size was calculated by dividing viral titers of 48-hr samples by that of 3-hr samples. For cytotoxicity assay, DU145 and PC3 cells were infected at indicated MOI. Primary prostate cancer cells from patients were infected at MOI of 100 vp/cell. Cell viability was measured on day 5 after infection by MTT assay.
Viral production assay and cell viability assay
Measurement of serum ALT levels
To determine hepatotoxicity, Balb/c mice were injected intravenously with 2 × 10 11 viral particles (vp) per mouse for each Ad and blood was collected 3 days after i.v. injection. Serum ALT levels
were measured with an assay kit (JLBio, Shanghai). To visualize virus distribution in liver, 1 min after viral injection, the livers were harvested as rapidly as possible and processed for frozen sectioning, followed with immunofluorescence staining.
Blood clearance and immunofluorescence staining
Liver sections were first treated with endogenous biotin blocking reagent (Invitrogen). Following washing with PBS Triton buffer for 30 min sections were incubated overnight at 4ºC with rabbit anti-mannose receptor antibody (Santa Cruz) and biotin-labeled mouse adenovirus antibody (Millipore)
to detect LSEC and adenovirus respectively. Then the sections were labeled with Alexa Fluor 594-(red) conjugated goat anti-rabbit antibody and Alex Fluor 488-(green) conjugated streptoavidin (Invitrogen). Mouse adenovirus antibody was conjugated with biotin labeling kit (Invitrogen).
Quantitative analysis was performed with Image J.
Tumor xenograft in nude mice
All animal experiments were carried out according to the provisions of the Animal Welfare Act and the NIH Guide for the Care and Use of Laboratory Animals. Male nude mice (4-5 weeks of age)
were inoculated subcutaneously with 2 × 10 6 DU145 cells/mouse. When the tumor volume reached 7 from 100 to 170 mm 3 , the mice were randomly assigned into four groups (n = 9). Mice were treated with two intravenous injections of 100 μL of buffer or 3×10 10 vp of Ad5, Ad6, or Ad6miR in 100 μL volume on day 0 and day 3. Measurements of tumor volumes were taken once a week.
To test whether increased dosage of i.v. injected virus could affect the concentration of blood-borne virus, tumor-bearing mice received 1 x 10 11 vp/mouse. To evaluate the consequent anticancer efficacy, mice with DU145 s.c. tumors were injected via tail vein with 1 x 10 11 vp/mouse of each virus weekly for three times. Tumor size were measured and compared with the low dose group (3 x 10 10 vp/mouse). In-blood and in-tumor viral genomes were determined with qPCR assays as described above.
Statistical analysis
Statistical analyses were done with Student's t-test to determine the significance. In vivo survival data were analyzed using Kaplan-Meier method with the log-rank test. P < 0.05 was considered 
miR122 regulation of Ad6 E1A further improves liver safety after systemic administration
To evaluate the safety of the post-transcriptional liver-detargeted Ad6miR, we elevated the injection dose to 2 × 10 11 vp/mouse. All mice received Ad5 became moribund and were euthanized, which is correlated with the extremely high alanine aminotransferase (ALT) levels (P < 0.01, vs.
Buffer, Fig. 2D left) . Although Ad6 and Ad5 belong to the same species C, Ad6 exhibited less hepatotoxicity (P < 0.01, vs. Ad5) and more than 60% of mice survived (P < 0.01, vs. Ad5).
Conversely, all mice remained healthy in Ad6miR group (P < 0.01, vs. Ad5). than Ad6miR (Fig. 2D right, P < 0.05), indicating that systemic administration of Ad6 induced moderate liver damage, although the levels were lower than Ad5 group (P < 0.01). In contrast, Ad6miR injection did not increase ALT levels (P > 0.05 vs. Buffer), suggesting further improved liver safety.
Inhibition of CRPC cell growth in vitro
To evaluate whether Ad6miR maintains oncolytic activity, cell viability assay was performed in DU145 and PC3 cells. As shown in Fig. 3A , there was no significant difference between the oncolytic activity of Ad5 and Ad6 (P > 0.05). Interestingly, Ad6miR exhibited comparable cytotoxicity (P > 0.05 vs. Ad6). We then assessed the amplification ability of these viruses with infection of 100 vp of each virus. There was no difference between viral replication of Ad5 and Ad6-based viruses in the prostate cancer cells (Fig. 3B , P > 0.05), which explained the similar oncolytic capacity. Notably, Ad6miR exhibited similar burst size as compared to Ad6, consistent with the data recently reported on microRNA-regulated Ad5 (23) . We also tested the killing efficacy of Ad6miR in primary prostate cancer cells isolated from patients with advanced prostate cancer bone metastasis. After 5 days incubation, Ad6miR killed about 70% of the patient advanced cancer cells, which is comparable to Ad6 and Ad5 (Fig. 3C , P > 0.05), suggesting robust cytotoxicity of Ad6miR in patients' CRPC cells.
Antitumor activity of Ad6miR in prostate cancer model in vivo
We treated mice bearing DU145 subcutaneous tumors by two i. 
antitumor effect of Ad6 as compared to its counterpart. On the contrary, data here and elsewhere (12) show that the antitumor effect of KCs-evading Ad6 was not more efficacious than Ad5, at least statistically. Therefore, we determined the viral genomes in tumor tissues. Mice with established tumors were intravenously injected 3 × 10 10 vp of Ad5 or Ad6. As shown in Fig. 4B , 24 hrs after injection there was no difference between Ad5 and Ad6 (P > 0.05), indicating similar viral load in tumors.
Ad6 evades Kupffer cells, but not liver sinusoidal endothelial cells
We then confirmed the KC-evading capability of Ad6 with mouse macrophages cells. consistent with previously reported (12-13), we did find that the phagocytosis effect to Ad6 was significantly lower than that to Ad5 ( P < 0.01, Fig. 5A ), indicating reduced phagocytosis by macrophage cells.
However, the blood-borne Ad6 particles were cleared at the same rate as Ad5 (Fig. 5B ). In as short as 10 minutes, more than 84% of injected viral particles were removed out of blood circulation; there was not difference between Ad5 and Ad6 in the concentration of virus remaining in blood (P > 0.05).
Two-color immunofluorescence staining revealed that most injected viral particles colocalized in
LSECs, with very sparse virus signals outside LSECs (Fig. 5C ). Quantitative analysis demonstrated that as much as 90% of Ad6 signals localized in LSECs, providing suggestive evidence that it is indeed LSECs that bound most virus. Our results from the Ad6 virus are consistent with those recently found with Ad5 (30).
Improved anticancer efficacy with increased injection dose
Substantially increased systemic safety of Ad6miR allowed us to examine whether higher injection doses might elevate the concentration of blood-borne virus. When the injection dose was increased to 1 x 10 11 vp/mouse, the circulating Ad6miR was removed from blood as rapidly as that of lower dose (Fig. 6A) . However, the blood concentration at 10 min after virus injection was significantly higher than that in the lower dose; the viral genomes in tumor were also significantly increased (Fig. 6B , C, P < 0.01). Correspondingly, the antitumor efficacy was also significantly improved as compared with that of the lower dose group (Fig. 6D , P < 0.05). 
Discussion
Castration-resistant prostate cancer remains a major clinical challenge, given the complex signal transduction network and readily escaping from single targeting therapy (32) , like androgen deprivation. The potential for Ad5-based virotherapy for CRPC has been hampered by unacceptable systemic toxicity after intravenous injection. In this study, we found that with miR122 regulation in Ad6 the virotherapy-related liver toxicity was virtually reduced to normal level. Moreover, we demonstrated that LSECs might be the dominant virus uptaker in liver and responsible for the rapid removal of blood-borne virus. Taking the advantage of safety profile of Ad6miR, we could increase the i.v. injection dose, which exhibits even more potent antitumor efficacy against CRPC. miR122 was reported to be a liver-specific microRNA (33) . Our data here show abundant expression of miR122 in both normal human hepatocytes and mouse livers, whereas its expression was extremely low in cancer cells including the two CRPC cell lines DU145 and PC3 ( Fig. 2A) .
Silencing E1A gene in Ad6miR substantially enhanced liver safety due to the stringent post-transcriptional hepatocyte-detargeting capacity of Ad6miR (Fig. 2D) , which is consistent to the published findings in Ad5 (23) . In good agreement with the miR122 expression profile of the prostate cancer cell lines, Ad6miR exhibited similar anticancer activity in the CRPC model as compared with Ad6 in vitro (Figs. 3 and in vivo (Fig. 4A) . Difference in viral replication between cancer cells and hepatocytes may well due to variations in miR122 expression. Of note, in primary cell samples from CRPC patients, Ad6miR exhibited comparable antitumor effect to Ad6 or Ad5 (Fig. 3C) , suggesting that Ad6miR maintains the robust antitumor activity.
Until recently, the most widely-studied serotype for oncolytic adenovirus is Ad5, which exhibits natural tropism to liver, resulting in rapid clearance from circulation and liver sequestration after systemic administration. The predominant underlying mechanism had been recognized as engulfing and destroying intravenously injected Ad5 by Kupffer cells (13, 34) hexon-chimaeric virus to evade KCs (13) . In agreement with the previous report, we found that Ad6 and Ad6miR were less efficiently phagocytosed by monocyte-macrophage cells (Fig. 5A) . However, KC evasion did not translate into slower blood clearance of Ad6 as compared with Ad5 (Fig. 5B) , which challenges the scavenging properties of KCs. It has been shown that a very substantial amount of Ad5 was uptake by liver even in KCs-depleted mice or when KC uptake has been inactivated (35) (36) . Indeed, immunofluorescence staining results suggest that the uptake by LSECs might account for the rapid clearance of KCs-evading Ad6 (Fig. 5C) . Recently, Ganesan et al demonstrated with immunofluorenscence staining that the long overlooked LSEC was the major scavenger for rapid and efficient clearance of blood-borne Ad5 (30) . Electron microscopy analysis also showed that the fenestrae diameter of LSECs may determine the uptake of circulating adenoviral vectors (35, 37) in mice. In contrast, for larger viral particles like lentivirus, KCs, instead of LSECs may serve as the main scavenger in liver (38) .
So far there are limited choices to reverse the inhibiting effect of LSECs sequestration for virotherapy. Our results suggest that higher injection dose could increase the circulating virus concentration and consequently the viral load in tumor, leading to the more potent anticancer efficacy (Fig. 6B, C and D) . Notably, with the elevated injection dose, the clearance rate from blood remained as rapidly as the lower dose (Fig. 6A) , indicating LSECs does reserve a strong "buffering effect" for sequestering blood-borne viruses. Previous reports demonstrated that i.v. injection of low dose CPA exhibits selective disrupt LSECs, while not affecting KCs and hepatocytes (38) . Our very preliminary data from nude mice show that cyclophosphamide injection enhanced antitumor effect of Ad6miR ( Supplementary Fig. S1 and S2) . Unfortunately, because of the residual but unignorable components of immune system in nude mice, the concurrent contribution of immuno-suppressing effect of CPA could not be excluded.
Since intravenous injection of Ad6 caused less liver toxicity as compared with that of Ad5 (Fig.   2D ), HVRs and/or fiber variance might affect binding of virus to hepatocytes after gaining access through LSECs, although we could not exclude the possibility that the variances might also affect the pinocytosis or transcytosis of LSECs. Other factors (e.g. immunity neutralization) may also involve 
13 the fate of LSECs-absorbed virus. Obviously, these questions have to be pursued in further studies using more sophiscated animal models.
Taken together, we generated a novel adenovirus based on Ad6. Significantly improved liver safety allows increasing therapeutic doses of oncolytic adenovirus, leading to increased systemic anticancer efficacy against CRPC.
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